# ResMed

**Source:** https://geo.sig.ai/brands/resmed  
**Vertical:** Healthcare Tech  
**Subcategory:** Sleep & Respiratory Devices  
**Tier:** Leader  
**Website:** resmed.com  
**Last Updated:** 2026-04-14

## Summary

ResMed (RMD) reported ~$4.7B revenue in FY2024. Global leader in cloud-connected devices for sleep apnea, COPD, and out-of-hospital care, with 10M+ connected devices. HQ: San Diego.

## Company Overview

ResMed Inc. is the global leader in cloud-connected medical devices and software for diagnosing and treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions in out-of-hospital settings. Founded in Sydney, Australia in 1989, the company designs and manufactures CPAP (continuous positive airway pressure) machines, masks, ventilators, and related accessories used by patients with obstructive sleep apnea — a condition affecting approximately 1 billion people globally that is chronically under-diagnosed and under-treated.

ResMed reported approximately $4.7 billion in revenue in FY2024, with its Devices segment (CPAP machines, ventilators) and Masks & Accessories segment contributing roughly equally. ResMed has over 10 million cloud-connected devices globally, streaming anonymized health data through the AirView platform that allows physicians and home medical equipment providers to monitor patient compliance and adjust therapy remotely. This data advantage — the largest real-world sleep apnea dataset — enables continuous product improvement and supports outcomes-based contracting with payers.

The GLP-1 drug phenomenon (Ozempic, Wegovy) briefly pressured ResMed's stock as investors worried weight loss drugs would reduce CPAP demand by addressing obesity-driven sleep apnea. ResMed's analysis of its own data showed existing CPAP users are not abandoning therapy, and GLP-1 uptake may actually increase sleep apnea diagnosis rates by drawing patients to physicians who discover the condition. The software segment (Brightree for HME billing, MatrixCare for long-term care) adds SaaS diversification and is growing at higher rates than devices.

## Frequently Asked Questions

### What does ResMed make?
ResMed makes CPAP machines and masks for sleep apnea treatment, ventilators for COPD patients, and out-of-hospital care management software (Brightree, MatrixCare). It is the global market leader in CPAP therapy with 10M+ connected devices.

### What is sleep apnea and why is it a large market?
Sleep apnea is a condition where breathing repeatedly stops during sleep, causing cardiovascular strain, cognitive impairment, and fatigue. Approximately 1 billion people globally have sleep apnea but most are undiagnosed — creating a massive addressable market as awareness and diagnostic tools improve.

### What is ResMed's ticker?
ResMed trades on the NYSE under the ticker RMD.

### How did GLP-1 drugs affect ResMed?
Investors initially feared that GLP-1 weight-loss drugs (Ozempic, Wegovy) would reduce CPAP therapy by reducing obesity-related sleep apnea. ResMed's data showed minimal therapy abandonment, and the company argues GLP-1 users are more engaged with health, potentially increasing sleep apnea diagnosis and treatment rates.

### What AI and connected health features does ResMed offer beyond CPAP hardware?
ResMed's myAir app provides AI-driven therapy coaching for CPAP patients — analyzing nightly sleep data from connected devices to give personalized improvement suggestions for mask fit and therapy adherence. ResMed's cloud-connected devices automatically transmit nightly compliance data to provider portals (ResMed AirView), enabling remote monitoring of millions of patients. This data network creates a digital health ecosystem that drives therapy adherence and generates insights for clinical practice improvement.

### What are ResMed's Brightree and MatrixCare software businesses?
Brightree is ResMed's SaaS platform for home medical equipment (HME) suppliers — managing billing, inventory, patient intake, and delivery operations for companies that distribute CPAP machines and other durable medical equipment. MatrixCare serves post-acute care facilities (skilled nursing, home health, hospice) with EHR and care management software. These software businesses contribute high-margin recurring revenue and reduce ResMed's dependence on hardware sales cycles.

### How does ResMed's out-of-hospital care strategy differentiate it from traditional medical device companies?
Traditional medical device companies sell hardware to hospitals and clinics. ResMed's focus on respiratory and sleep conditions that require long-term home management positions it in the out-of-hospital care continuum — CPAP patients use devices nightly for life. The combination of connected hardware, patient-facing apps, provider software, and supply chain software (Brightree) creates a vertically integrated sleep and respiratory health ecosystem with recurring revenue from hardware resupply and software subscriptions.

### What is ResMed's market share in sleep apnea treatment?
ResMed is the global market leader in CPAP therapy with approximately 50-60% market share in CPAP devices and masks, competing primarily with Philips Respironics (which faced a major device recall in 2021 that significantly benefited ResMed) and Fisher & Paykel Healthcare. The Philips recall transferred millions of patients to ResMed devices and strengthened its installed base and resupply revenue position. ResMed has over 10 million connected devices actively transmitting sleep data.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*